Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 4
1(25.0%)
N/A
1(25.0%)
4Total
Phase 3(2)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03043820Phase 3Completed

Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder

Role: lead

NCT01999309Phase 3Completed

Simvastatin Addition for Patients With Recent-onset Schizophrenia

Role: lead

NCT01977521Not ApplicableUnknown

Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations

Role: lead

NCT02460965Unknown

Understanding Hallucinations (Part II)

Role: lead

NCT01764672Phase 4Withdrawn

Effect of Methylphenidate on Connectivity

Role: lead

All 5 trials loaded